Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Receivables (2023 - 2024)

Capricor Therapeutics has reported Receivables over the past 3 years, most recently at $20.4 million for Q4 2024.

  • Quarterly results put Receivables at $20.4 million for Q4 2024, changed 0.02% from a year ago — trailing twelve months through Dec 2024 was $20.4 million (changed 0.02% YoY), and the annual figure for FY2024 was $20.0 million, down 1.83%.
  • Receivables for Q4 2024 was $20.4 million at Capricor Therapeutics, roughly flat from $20.4 million in the prior quarter.
  • Over the last five years, Receivables for CAPR hit a ceiling of $20.4 million in Q4 2023 and a floor of $20.4 million in Q4 2024.